Objective

2

To observe the clinical efficacy of Zhibitai capsule in the treatment of dyslipidemia with phlegm-stasis binding pattern

in order to evaluate its effectiveness and safety.

Method

2

Totally 82 patients of dyslipidemia with phlegm-stasis binding pattern were selected from the outpatient department of internal medicine in Hospital of Xidian University from July 2018 to July 2019. According to the random number table method

they were divided into control group and observation group

with41 cases in each group. Control group was treated with aAtorvastatin calcium

and observation group was treated with Zhibitai capsules. The changes in blood lipid index

liver function and renal function were measured before and after 8-week treatment in two groups

the efficacy on traditional Chinese medicine (TCM) syndromes and clinical symptom scores before and after treatment were compared between two groups

and the adverse reactions

such as liver pain and muscle pain

were recorded among patients.

Result

2

The changes of blood lipids were compared after 8 weeks of treatment

total cholesterol (TC)

triglyceride (TG)

and low-density lipoprotein cholesterol (LDL-C) were all lower than before

while high-density lipoprotein cholesterol (HDL-C) was increased

(P<

0.05)

the total effective rate in control group was 90.24% (37/41)

which was 92.68% (38/41) in observation group

with no significant difference between two groups

in the TCM syndrome scores of two groups before and after treatment

four common TCM syndromes

namely scores dizziness

chest tightness

head heavy as if swathed and chest fullness

were decreased (

P

<

0.05). In terms of the efficacy of two groups of TCM syndromes

the total effective rate in control group was 87.80% (36/41)

which was 92.68% (38/41) in observation group

with no statistically significant difference between two groups. Control group had 3 cases of increased transaminase

but none of them beyond 2 times of the normal upper limit

and observation group had 1 case of mild abdominal distension and nausea

which did not affect continued medication. No muscle pain or liver pain occurred in two groups.

Conclusion

2

Zhibitai capsule is effective in treating dyslipidemia

which is comparable to atorvastatin calcium in treating dyslipidemia

with the safety and reliability.